Literature DB >> 12546613

Validity and clinical utility of the aspartate aminotransferase-alanine aminotransferase ratio in assessing disease severity and prognosis in patients with hepatitis C virus-related chronic liver disease.

Edoardo Giannini1, Domenico Risso, Federica Botta, Bruno Chiarbonello, Alberto Fasoli, Federica Malfatti, Paola Romagnoli, Emanuela Testa, Paola Ceppa, Roberto Testa.   

Abstract

BACKGROUND: The aspartate aminotransferase-alanine aminotransferase ratio (AST/ALT ratio) has been used to noninvasively assess the severity of disease in patients with chronic liver disease (CLD). We previously demonstrated that progressive liver functional impairment is associated with an increase in the AST/ALT ratio.
OBJECTIVES: To evaluate the reproducibility and transportability of the AST/ALT ratio in a large cohort of patients with different degrees of hepatitis C virus (HCV)-related CLD, to confirm the correlation between progressive impairment of liver function and increase in the AST/ALT ratio, to evaluate whether diagnostic accuracy of the ALT/AST ratio can be improved by using it with other biochemical variables, and to assess the 1-year prognostic capability of the AST/ALT ratio in patients with liver cirrhosis. PATIENTS AND METHODS: We retrospectively evaluated 252 patients with HCV-related CLD. The AST/ALT ratio was correlated with the degree of liver fibrosis in patients with chronic hepatitis and with the Child-Pugh score in patients with cirrhosis. All patients had undergone monoethylglycinexylidide (MEGX) testing to evaluate liver function. We assessed the prognostic ability of the AST/ALT ratio in a subset of 63 cirrhotic patients who were followed up for at least 1 year.
RESULTS: The AST/ALT ratio was more frequently 1 or higher in cirrhotic patients (P<.001). There was a significant correlation between MEGX values and the AST/ALT ratio (r(s) = -0.621, P<.001). Multivariate stepwise logistic analysis showed that AST/ALT ratio, platelet count (PLT), MEGX values, and prothrombin activity were independently associated with the presence of cirrhosis. Combined assessment of the AST/ALT ratio and/or PLT obtained 97.0% positive predictive value and 97.9% negative predictive value for the diagnosis of cirrhosis. The AST/ALT ratio had 81.3% sensitivity and 55.3% specificity in identifying cirrhotic patients who died within 1-year of follow-up.
CONCLUSIONS: The AST/ALT ratio is both reproducible and transportable in patients with HCV-related CLD. The AST/ALT ratio is correlated with both histologic stage and clinical evaluation. Progressive liver functional impairment is reflected by an increase in the AST/ALT ratio. Noninvasive evaluation by means of the combined AST/ALT ratio and PLT assessment misclassifies only a few cirrhotic patients. In cirrhotic patients, the AST/ALT ratio provides medium-term prognostic information that is no different from that provided by established prognostic scores.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12546613     DOI: 10.1001/archinte.163.2.218

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  87 in total

1.  Advanced hepatocellular carcinoma: which staging systems best predict prognosis?

Authors:  Fidel-David Huitzil-Melendez; Marinela Capanu; Eileen M O'Reilly; Austin Duffy; Bolorsukh Gansukh; Leonard L Saltz; Ghassan K Abou-Alfa
Journal:  J Clin Oncol       Date:  2010-05-10       Impact factor: 44.544

2.  Simple tests to predict hepatic fibrosis in nonalcoholic chronic liver diseases.

Authors:  Woon Geon Shin; Sang Hoon Park; Sun-Young Jun; Jae One Jung; Joon Ho Moon; Jong Pyo Kim; Kyoung Oh Kim; Cheol Hee Park; Tai Ho Hahn; Kyo-Sang Yoo; Jong Hyeok Kim; Choong Kee Park
Journal:  Gut Liver       Date:  2007-12-31       Impact factor: 4.519

3.  Effects of fingolimod treatments on alanine transaminase and aspartate transaminase levels in patients with multiple sclerosis.

Authors:  Saeid Sadeghi Joni; Masoumeh Cheshmavar; Pouria Shoureshi; Zohreh Zamani; Niusha Taoosi; Morteza Akbari; Mahdieh Afzali
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2020-06-15

4.  Correlates of high hepatitis C virus RNA load in a cohort of HIV-negative and HIV-positive individuals with haemophilia.

Authors:  S M Gadalla; L R Preiss; M E Eyster; J J Goedert
Journal:  J Viral Hepat       Date:  2011-03       Impact factor: 3.728

Review 5.  Liver enzyme alteration: a guide for clinicians.

Authors:  Edoardo G Giannini; Roberto Testa; Vincenzo Savarino
Journal:  CMAJ       Date:  2005-02-01       Impact factor: 8.262

6.  Sequential algorithms combining non-invasive markers and biopsy for the assessment of liver fibrosis in chronic hepatitis B.

Authors:  Giada Sebastiani; Alessandro Vario; Maria Guido; Alfredo Alberti
Journal:  World J Gastroenterol       Date:  2007-01-28       Impact factor: 5.742

7.  Clinical Utility of Biomarkers of Liver Fibrosis.

Authors:  Keyur Patel; Don C Rockey
Journal:  Gastroenterol Hepatol (N Y)       Date:  2006-01

Review 8.  Noninvasive assessment of portal hypertension in cirrhosis: liver stiffness and beyond.

Authors:  Horia Stefanescu; Bogdan Procopet
Journal:  World J Gastroenterol       Date:  2014-12-07       Impact factor: 5.742

9.  Efavirenz concentrations in HIV-infected patients with and without viral hepatitis.

Authors:  Sofia A Pereira; Umbelina Caixas; Teresa Branco; Isabel Germano; Fátima Lampreia; Ana L Papoila; Emília C Monteiro
Journal:  Br J Clin Pharmacol       Date:  2008-06-09       Impact factor: 4.335

Review 10.  Non-invasive diagnosis of liver fibrosis in chronic hepatitis C.

Authors:  Leonardo de Lucca Schiavon; Janaína Luz Narciso-Schiavon; Roberto José de Carvalho-Filho
Journal:  World J Gastroenterol       Date:  2014-03-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.